This week new facilitations and limitations in connection with COVID-19 were introduced in Poland. They include the exemption from taxes on import and intracommunity purchase of selected goods and a new ban on the export of...more
4/9/2020
/ Coronavirus/COVID-19 ,
Countervailing Duties ,
Export Controls ,
Exports ,
Federal Bans ,
Goods or Services ,
Imports ,
Medical Devices ,
Medical Supplies ,
Personal Protective Equipment ,
Poland ,
Tax Exemptions
We are pleased to provide you with the third annual installment of our Life Sciences and Health Care Horizons guide. For each of these guides, we have asked our industry thought leaders throughout the world to write about...more
2/26/2020
/ 3D Printing ,
AIDS ,
Analytics ,
Artificial Intelligence ,
Biosimilars ,
Biotechnology ,
Blockchain ,
California Consumer Privacy Act (CCPA) ,
Cyber Threats ,
Cybersecurity ,
Data Breach ,
Department of Defense (DOD) ,
Digital Health ,
Drug Distribution ,
Drug Pricing ,
EU ,
Federal Funding ,
Food and Drug Administration (FDA) ,
General Data Protection Regulation (GDPR) ,
Health Technology ,
HIV ,
Incident Response Plans ,
Intellectual Property Protection ,
Life Sciences ,
Medical Device Data System ,
Medical Devices ,
Medical Software ,
Over The Counter Drugs (OTC) ,
Pharmaceutical Industry ,
PHI ,
Prescription Drugs ,
Procurement Guidelines ,
Regulatory Standards ,
Research and Development ,
Right to Try ,
Robotics ,
Supply Chain ,
Telehealth
The President of the Polish Office for the Registration of Medicinal Products, Medical Devices, and Biocidal Products issued two more Brexit related communiques....more
4/2/2019
/ Biotechnology ,
Imports ,
Licensing Rules ,
Life Sciences ,
Manufacturers ,
Marketing ,
Medical Devices ,
No-Deal Brexit ,
Pharmaceutical Industry ,
Poland ,
Regulatory Standards ,
Trade Policy ,
UK Brexit
On 1 March 2019, the President of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products issued yet another communique concerning consequences of Brexit, this time with respect to the...more
3/5/2019
/ Biosimilars ,
EU ,
Healthcare ,
Life Sciences ,
Medical Devices ,
Medical Reimbursement ,
No-Deal Brexit ,
Pharmaceutical Industry ,
Poland ,
Regulatory Standards ,
UK ,
UK Brexit